Kendall Law Group Investigates Cypress Bioscience, Inc. Acquisition For Shareholders

Kendall Law Group, a national securities firm led by a former federal judge and a former U.S. Attorney, is investigating Cypress Bioscience, Inc. (NASDAQ: CYPB) for shareholders in connection with the proposed acquisition of the company by Ramius, LLC, a private investment company. If you are a Cypress shareholder and would like additional information about your rights, contact the Kendall Law Group at 877-744-3728 or by email at [e-mail].

On July 19, 2010, Ramius, already a 9.9 percent owner of Cypress stock, offered to buy the rest of the company for $4 per share. Cypress stock has traded for as high as $5.20 in the last three months. After entering into an exclusive North American license for the development and commercialization of BioLineRx's novel antipsychotic BL-1020/CYP-1020, Cypress stock prices dropped dramatically. The company justified the agreement calling the new drug a “potential breakthrough treatment for schizophrenia.”

Kendall Law Group was founded by a former federal judge, includes a former United States Attorney, prosecutors and securities lawyers who are experienced in complex securities litigation. The firm has been counsel in numerous merger and acquisition cases nationwide, including some of the largest transactions in the United States.

>To order reprints of this article, click here: Reprints